Pourmoghaddas Ali, Dormiani-Tabatabaei Mehrnaz, Sadeghi Masoumeh, Kermani-Alghoraishi Mohammad, Golshahi Jafar, Shokouh Pedram
Associate Professor, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atheroscler. 2015 Jan;11(1):36-42.
This study aimed to evaluate the effect of pioglitazone as an insulin sensitizer on circulating interleukin-10 (IL-10) as an anti-inflammatory factor and tumor necrosis factor-alpha (TNF-α) as main proinflammatory factor in non-diabetic metabolic syndrome (MetS) patients in Caucasians race of Middle East area in Iran.
We conducted a randomized double-blind controlled study of 68 non-diabetic patients with MetS. Patients were randomly divided into two groups including intervention group received pioglitazone 30 mg daily for 24 weeks, and the control group received placebo pills for the same duration. Circulating levels of TNF-α and IL-10 were assessed as a primary goal. Lipid profile, liver enzymes, blood pressure (BP), waist circumference, and body mass index (BMI) also were measured.
Lipid profile and fasting blood sugar had non-significant changes after treatment by pioglitazone, but BMI was increased significantly (P = 0.002). BP and waist circumference had a significant decrease in both groups (P < 0.050). Aspartate transaminase and alanine transaminase were decreased significantly in the pioglitazone group (P = 0.002). TNF-α decreased non-significantly in both groups (P > 0.050). IL-10 increased in intervention group non-significantly (P = 0.971); whereas in placebo group decreased to a little extent (P = 0.401). C-reactive protein was also decreased insignificant after receive pioglitazone (P = 0.333). There was no significant difference in all variables between the two groups (P > 0.050) except liver enzymes (P < 0.050).
This study indicates that the pioglitazone has no positive effect on improving inflammatory status in the non-diabetes patients with MetS.
本研究旨在评估吡格列酮作为胰岛素增敏剂，对伊朗中东地区高加索人种非糖尿病代谢综合征（MetS）患者循环中抗炎因子白细胞介素-10（IL-10）和主要促炎因子肿瘤坏死因子-α（TNF-α）的影响。
我们对68例非糖尿病MetS患者进行了一项随机双盲对照研究。患者被随机分为两组，干预组每天服用30毫克吡格列酮，持续24周，对照组服用相同疗程的安慰剂。评估TNF-α和IL-10的循环水平作为主要目标。还测量了血脂、肝酶、血压（BP）、腰围和体重指数（BMI）。
吡格列酮治疗后血脂和空腹血糖无显著变化，但BMI显著增加（P = 0.002）。两组的BP和腰围均显著降低（P < 0.050）。吡格列酮组的天冬氨酸转氨酶和丙氨酸转氨酶显著降低（P = 0.002）。两组的TNF-α均无显著降低（P > 0.050）。干预组的IL-10无显著增加（P = 0.971）；而安慰剂组略有下降（P = 0.401）。服用吡格列酮后C反应蛋白也无显著降低（P = 0.333）。除肝酶外（P < 0.050），两组所有变量均无显著差异（P > 0.050）。
本研究表明，吡格列酮对改善非糖尿病MetS患者的炎症状态没有积极作用。
